Detalhe da pesquisa
1.
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare.
J Intern Med
; 295(3): 281-291, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38098165
2.
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
Value Health
; 26(4): 508-518, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442831
3.
Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge.
Alzheimers Dement
; 19(5): 1800-1820, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36284403
4.
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States.
Vaccines (Basel)
; 12(1)2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38250887
5.
Evaluating Elements of the Care Partner Experience in Individuals Who Care for People with Alzheimer's Disease Across the Severity Spectrum.
Neurol Ther
; 13(1): 53-67, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37889399
6.
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Pharmacoeconomics
; 42(6): 693-714, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38684631
7.
Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes.
J Comp Eff Res
; 11(18): 1349-1363, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36317935
8.
Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
Vaccine
; 40(3): 483-493, 2022 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933763
9.
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Pharmacoeconomics
; 40(3): 323-339, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921350
10.
Estimated Public Health Impact of the Recombinant Zoster Vaccine.
Mayo Clin Proc Innov Qual Outcomes
; 5(3): 596-604, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195552
11.
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
Neurol Ther
; 10(2): 919-940, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426940
12.
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
J Manag Care Spec Pharm
; 26(12): 1567-1575, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33043821